Author(s)

Younes Moutakiallah, Mehdi Bamous, Roland Henaine, Jacques Robin, Jean François Obadia, Jean Ninet

.
Department of Cardiac Surgery, C. Louis Pradel Cardiologic Hospital, Lyon, France.

Background: The use of low molecular weight heparin for early anticoagulation after mechanical aortic valve replacement is still a matter of debate even more that the early postoperative phase is associated with maximum of thrombo-embolic and bleeding risks. The objective of this study is to verify the efficacy and the safety of low molecular weight heparin for the early anticoagulation after mechanical aortic valve replacement. Methods and Results: It is a prospective study conducted over 6 months and interested 40 consecutive patients (32 male and 8 female) with a mean age 53.83 ± 16.93 years (19-75 years) who underwent a mechanical aortic valve replacement and received enoxaparin as bridging therapy between continuous unfractionated heparin and fully effective vitamin K antagonist therapy. There was no in-hospital death and no in-hospital thromboembolic events. We report 2 major bleeding events (5%). Conclusion: The use of low molecular weight heparin should be an alternative to explore for early anticoagulation after valve heart surgery and the results of our study must be verified by large randomized studies before drawing any hasty conclusions.

Early Anticoagulation, Mechanical Aortic Valve Replacement, Low Molecular Weight Heparin

Moutakiallah, Y. , Bamous, M. , Henaine, R. , Robin, J. , Obadia, J. and Ninet, J. (2014) Early Postoperative Anticoagulation by Enoxaparin after Mechanical Aortic Valve Replacement. World Journal of Cardiovascular Surgery, 4, 109-115. doi: 10.4236/wjcs.2014.47017.